3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
10
Non-metastatic Castration-resistant Prostate Cancer
2
Metastatic Hormone-sensitive Prostate Cancer
2
Breast Neoplasms
2
Salivary Gland Neoplasms
1
Prostate Cancer Non-Metastatic
1
Non-metastatic Prostate Cancer
1
Neoplasms
1
Healthy Volunteers
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Cancer Female
1
Biochemically Recurrent Prostate Cancer
1
Advanced Prostate Carcinoma
1
Interventions
Docetaxel
3
Androgen Antagonists
3
darolutamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Metastatic Hormone-sensitive Prostate Cancer
×
darolutamide
×
Clear all
NCT02799602
2025-12-04
ARASENS
Bayer
Phase 3
Completed
1,306 enrolled
25 charts
2 FDA
NCT06498921
2024-10-24
BELBEQA
Bayer
Completed
106 enrolled